ArticleJournal of cardiovascular development and disease2026
Prognostic Significance of New-Onset Atrial Fibrillation Burden in Acute Myocardial Infarction Patients: A Comparison Based on Left Ventricular Ejection Fraction.
Article in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute myocardial infarction (AMI) with reduced or preserved left ventricular ejection fraction (LVEF) is associated with distinct prognoses and differing risk factor profiles. However, the use of new-onset atrial fibrillation (NOAF) burden in risk stratification of AMI patients, particularly across LVEF subgroups, remains unclear. We analyzed consecutive AMI patients without prior AF who developed their first in-hospital AF episode between 2014 and 2022. The patients were stratified by LVEF (AMIrEF: <40%; AMIpEF: ≥40%) and AF burden (>10.87% vs. ≤10.87%). The primary endpoint was a major adverse cardiovascular event (MACE), including cardiovascular death and heart failure hospitalization. Among 644 patients with LVEF data, 178 (27.6%) were AMIrEF and 466 (72.4%) were AMIpEF; 248 (38.5%) had a high AF burden. Over a median follow-up time of 4.2 years, the MACE incidence was 18.9 and 23.0 per 100 person-years in low- and high-burden AMIrEF patients, and 7.2 and 17.5 in AMIpEF patients, respectively. After multivariable adjustment, a high NOAF burden was significantly associated with increased MACE in AMIpEF patients [hazard ratio (HR): 2.63, 95% confidence interval (CI): 1.82-3.79], but not in AMIrEF patients [HR: 1.29, 95% CI: 0.79-2.10]. Propensity-matched analysis yielded concordant results [AMIrEF: 1.15 (0.69-1.90); AMIpEF: 2.45 (1.75-3.45)]. In conclusion, a high NOAF burden is strongly associated with adverse long-term cardiovascular outcomes in AMIpEF patients, highlighting its potential utility for risk stratification in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.